gdc
PSSGuide_2021
Myelodysplastic Syndromes

Drugs for Myelodysplastic Syndromes

Here are the drugs and financial support services available to patients receiving treatment for Myelodysplastic Syndromes.

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis
800-245-5356

Gleevec is a kinase inhibitor used for the treatment of patients with myelodysplastic syndromes or myeloproliferative disease associated with PDGFR gene rearrangements, as determined by an FDA-approved test.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleevec:

Novartis Oncology Universal Co-pay Program

Eligible patients with private insurance may pay only $10 for a 30-day supply of Gleevec, with a maximum benefit of $10,630 per 30-day supply up to an annual maximum benefit of $30,000.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Gleevec for free through the Novartis Patient Assistance Foundation. To be eligible for financial assistance, the patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Gleevec for free until prescription drug coverage becomes available to them.

Inqovi (decitabine + cedazuridine) Tablets

Drug company: Taiho Oncology
844-824-4648

Inqovi is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, used for treatment of adults with myelodysplastic syndromes (MDS), including previously treated and untreated MDS with refractory types of anemia, and chronic myelomonocytic leukemia, and intermediate-risk or high-risk MDS.

Taiho Oncology offers 2 financial assistance programs for patients who have been prescribed Inqovi:

Taiho Oncology Patient Support Co-pay Assistance Program

Eligible patients who have commercial (or private) insurance may have a $0 copay per treatment cycle of Inqovi, for a maximum benefit limit of $6,000 per month and $36,000 per year.

Patient Assistance Program

This program offers financial assistance for eligible patients who are uninsured or underinsured and who have insufficient financial resources to pay for Inqovi. Patients may receive Inqovi for free based on assistance, financial, and medical criteria.

Revlimid (lenalidomide) Capsules

Drug company: Celgene
800-931-8691

Revlimid is a thalidomide analog used for the treatment of transfusion-dependent anemia caused by low- or intermediate-risk myelodysplastic syndromes that is associated with a deletion 5q cytogenetic abnormality, with or without additional cytogenetic abnormalities.

Celgene Patient Support offers 3 financial assistance programs for patients using Revlimid:

Celgene Commercial Co-pay Program

This program reduces the cost of the copay for Revlimid to $25 or less for patients who have private insurance.

Celgene Patient Assistance Program

Patients with no insurance, or not enough insurance to cover their medication, who meet certain financial criteria may be able to receive Revlimid for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Vidaza (azacitidine)

Drug company: Celgene
800-931-8691

Vidaza is a nucleoside metabolic inhibitor used for the treatment of patients with chronic myelomonocytic leukemia, a type of myelodysplastic syndromes.

Celgene Patient Support offers 2 financial assistance programs for patients using Vidaza:

Celgene Patient Assistance Program

Patients with no insurance, or not enough insurance to cover their medication, who meet certain financial criteria, may be able to receive Vidaza for free.

Celgene Patient Support

This program connects patients with public insurance, or with commercial insurance, to outside resources that may help them with the cost of copays, deductibles, and insurance premiums.

Table. Drugs Prescribed for Myelodysplastic Syndromes

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services



Share this:

Last modified: April 7, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country